

EPAA 3Rs Awards and Grants 2021 REFINEMENT PRIZE 2021

HaPILLnes

S

PRECISE VOLUNTARY ORAL DRUG DOSING IN RODENTS - AN INNOVATIVE 3Rs APPROACH











Laboratory Animal Sciences


The **science and technology** dealing with the procurement, breeding, **care**, **health**, and selection of **animals used in biomedical research and testing**.




TRANSLATION & REPRODUCIBILITY CRISIS








Because ≈ 9 million animals are used in E.U. every year for research purposes



In humans

In pre-clinical studies





Oral dosing is part of the daily routine for millions of laboratory animals

Nowadays:

GAVAGE



- 1. Restrain the animal
- 2. **Insert** cannula into the animal's stomach
- 3. **Press** the syringe plunger to **inject** the drug to the animal's stomach



Stress Produced by Gavage Administration in the Rat

ALAN P. BROWN, PHD, DABT, NANCY DINGER, BS, AND BARRY S. LEVINE, DSC, DABT


Does the Stress of Laboratory Life and Experimentation on Animals Adversely Affect Research Data? A Critical Review

Jarrod Bailey

Gavage-Related Reflux in Rats: Identification, Pathogenesis, and Toxicological Implications (Review)

Siegrid Damsch¹, Gary Eichenbaum², Alfred Tonelli², Lieve Lammens¹, Kathleen Van den Bulck¹, Bianca Feyen¹, John Vandenberghe¹, Anton Megens¹, Elaine Knight², and Michael Kelley²

Gavage induces physiologic stress



Thus, gavage conditions the observed metrics in pre-clinical studies

Journal of Natural Science, Biology and Medicine

Regulation of adult neurogenesis in the hippocampus by stress, acetylcholine and dopamine B. S. Shankaranarayana Rao', B. N. Srikumar²

Scientific and Regulatory Policy Committee Review

Interpreting Stress Responses during Routine Toxicity Studies: A Review of the Biology, Impact, and Assessment

Nancy E. Everds¹, Paul W. Snyder², Keith L. Bailey³, Brad Bolon⁴, Dianne M. Creasy⁵, George L. Foley⁶, Thomas J. Rosol⁷, and Teresa Sellers⁸

OPEN The role of the microbiome and psychosocial stress in the expression and activity of drug metabolizing enzymes in mice



Nina Zemanová¹, Pavel Anzenbacher², Iveta Zapletalová², Lenka Jourová^{1™}, Petra Hermanová³, Tomáš Hudcovic³, Hana Kozáková³, Martin Vodička⁴, Jiří Pácha⁴ & Fva Anzenbacherová³

Neurobiology of Disease

Stress-Induced Recruitment of Bone Marrow-Derived Monocytes to the Brain Promotes Anxiety-Like Behavior

Eric S. Wohleb, 1,2 Nicole D. Powell, 1 Jonathan P. Godbout, 2,3,4 and John F. Sheridan 1,3,4

Clinical and Developmental Immunology


Review Article

Neuroendocrine Immunoregulation in Multiple Sclerosis

Nathalie Deckx, Wai-Ping Lee, Zwi N. Berneman, and Nathalie Cools

Over the years, many alternatives have been developed such as:

Drug suspension in sucrose solution and voluntary syringe feeding



Atcha et al. 2010

Fast dissolving oral drug biofilm and voluntary syringe feeding



Yardley et al. 2015

Drug given in highly caloric and palatable substances (e.g. Nutella, peanut butter, sugar paste)

Drug given in food/drinking water



Limitations

- Lack of dose precision
- Requires single-housing
- Requires animal restraint
- Metabolically disruptive




Sobolewski et al. 2016



jko et al. 2017

So, we proposed ourselves to find a truly voluntary, stress free and metabolic inert alternative



To help implement the 3R's principles of Refinement and Reduction in oral drug dosing

2 PRECISE ORAL DOSING


3 STRESS FREE

4 METABOLIC INOCUITY

5 SAFETY



























Animal model of disease:

cuprizone intoxication multiple sclerosis model



-e · Control + empty-PILL


-B · MS mouse model + empty-PILL


-A · MS mouse model + Sitagliptin PILL-dosed (50mg/Kg)

180
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120
120


Day

PRECISE ORAL DOSING







STRESS FREE








Elevated Plus Maze
















STRESS FREE




Direct physiologic readout




Acute: 30min postgavage

METABOLIC INOCUITY




SAFETY

Liver function profile




Kidney function profile



Creatinine(mg/dL)

SAFETY

Histology of liver and kidney sections



PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY PCT WRITTEN OPINION OF THE see form PCT/ISA/220 INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) Date of mailing (day/month/year) see form PCT/ISA/210 (second sheet) Applicant's or agent's file reference FOR FURTHER ACTION See paragraph 2 below see form PCT/ISA/220 International application No International filing date (day/month/year) Priority date (day/month/year) PCT/IB2021/053124 15.04.2021 27.04.2020 International Patent Classification (IPC) or both national classification and IPC INV. A61K9/20 A23K10/30 A61K31/40 A61K31/4985 A61K31/505 A01N25/08 A01P11/00

UNIVERSIDADE DE COIMBRA Prior art documents

1	Reference	ie made to	the following	documents:

- EP 0 772 391 A1 (ZENECA LTD [GB]) 14 May 1997 (1997-05-14)
- US 2005/181003 A1 (ENDEPOLS STEFAN [DE] ET AL) 18 August 2005 (2005-08-18)
- DHAWAN SANDEEP S ET AL: "Oral dosing of rodents using a palatable tablet", PSYCHOPHARMACOLOGY, vol. 235, no. 5, 6 March 2018 (2018-03-06), pages 1527-1532, cited in the application
- RAYA JULIANA ET AL: "Corticosterone Assimilation by a Voluntary Oral Administration in Palatable Food to Rats", JOURNAL OF APPLIED ANIMAL WELFARE SCIENCE, vol. 22, no. 1, 11 May 2018 (2018-05-11),

Re Item V

Novelty (Article 33(1) in the sense of Article 33(2) PCT)

Consequently, the subject-matter of Claims 1-15 can be considered novel in the sense of Article 33(2) PCT.

Inventive Step (Article 33(1) in the sense of Article 33(3) PCT)

Since there was no hint or suggestion towards the specific formulation of Claim 1 and since the demonstrated high voluntary acceptance of the formulation was not obviously derivable from any of the prior art documents or their combinations, it appears that an inventive step can be acknowledged for the subject-matter of Claim 1.

For the same reason, the subject-matter of Claims 2-15 also appears to involve an inventive step.

Consequently, the subject-matter of Claims 1-15 appears to meet the requirements of Article 33(3) PCT.



Sofia Viana, PhD Inventor/supervisor



Inês Preguiça, HaPILLness PhD student



Flávio Reis, PhD Inventor/Cosupervisor



Sara Nunes, PhD student André Alves, PhD student Pedro Vieira, MSc Carolina Ferreira, MSc Beatriz Ormonde, MSc student

Funding: 2020.08560.BD FLOT

